SIGA Technologies is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. The Company's lead product is TPOXX an orally administered antiviral drug that targets orthopoxvirus infections. While TPOXX is not yet approved as safe or effective by the U.S. Food & Drug Administration, it is a novel small-molecule drug that is being delivered to the U.S. Strategic National Stockpile under the Project BioShield Act of 2004.
|HQ||New York, US||Map|
EBIT (Q1, 2019)
Market capitalization (10-Jun-2019)
Closing stock price (10-Jun-2019)
|USD||Q3, 2013||Q1, 2014||Q2, 2014||Q3, 2014||Q1, 2015||Q2, 2015||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017|
|USD||Q3, 2013||Q1, 2014||Q2, 2014||Q3, 2014||Q1, 2015||Q2, 2015||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017||Q3, 2017||Q1, 2018||Q2, 2018||Q3, 2018||Q1, 2019|
Cash From Operating Activities
How many employees does SIGA Technologies have?
SIGA Technologies has 41 employees.
What is SIGA Technologies revenue?
Latest SIGA Technologies annual revenue is $477.1 m.
What is SIGA Technologies revenue per employee?
Latest SIGA Technologies revenue per employee is $11.6 m.
Who are SIGA Technologies competitors?
Competitors of SIGA Technologies include Obsidian Therapeutics, Mymetics and Elite Pharmaceuticals.
Where is SIGA Technologies headquarters?
SIGA Technologies headquarters is located at 660 Madison Ave #1700, New York.
Where are SIGA Technologies offices?
SIGA Technologies has offices in New York and Corvallis.
How many offices does SIGA Technologies have?
SIGA Technologies has 2 offices.